Day One Biopharmaceuticals, Inc. — Investor Relations & Filings

Day One Biopharmaceuticals is a commercial-stage company dedicated to developing and commercializing targeted therapies for people of all ages with cancer, with a particular focus on pediatric populations. The company's mission is to disrupt traditional drug development paradigms to accelerate the delivery of new medicines to patients with urgent needs. Employing a 'search and development' strategy, Day One identifies, acquires, and advances promising first- or best-in-class treatments. Its lead commercial product, tovorafenib, is a therapy developed for pediatric low-grade glioma (pLGG). The company collaborates with clinical oncologists, scientists, and patient communities to address unmet needs in both childhood and adult cancers with equal intensity.